查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1363011

碳青黴烯類市場規模、佔有率和趨勢分析報告：按藥物類別、用途、配銷通路、地區和細分市場預測，2023-2030

Carbapenem Market Size, Share & Trends Analysis Report By Drug Class (Meropenem, Imipenem, Ertapenem), By Application (UTI, Blood Stream Infections, Pneumonia), By Distribution Channel, By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 236 Pages | 商品交期: 2-10個工作天內

價格

碳青黴烯市場成長與趨勢：

Grand View Research, Inc.最新報告顯示，預計到2030年，全球碳青黴烯類市場規模將達到52.4億美元，2023年至2030年年複合成長率為4.78%。

碳青黴烯類使用量的增加、抗生素處方率的增加以及由於研發進步而出現的新藥是預計在預測期內推動市場成長的一些要素。

根據美國肺臟協會 2022 年 11 月發表的一篇論文，肺炎的流行程度比人們普遍認知的要高，年度導致超過 100 萬人住院，5 萬人死亡。 2023 年 5 月，Antavio 開始了一項 I 期研究，為健康志願者給藥第一給藥抗生素治療醫院感染。該治療方法被稱為 MEM-ANT3310，將美羅培南 (MEM) 與 Antavio 的新型廣譜絲氨酸 BETA-內醯胺酶抑制劑 ANT3310 結合。這將推動預測期內的市場成長。

此外，在大流行期間，世界各地的衛生系統在管理 COVID-19 重症病例方面面臨巨大挑戰，特別是在 ICU 環境中。許多重症 COVID-19 患者需要先進的醫療護理，包括使用抗生素來應對繼發細菌感染。碳青黴烯類是強效廣效抗生素，是這些患者細菌感染疾病的治療選擇之一。因此，COVID-19 大流行期間對市場產生了重大影響。

北美，特別是美國的藥品法律規範非常完善，為藥品核准提供了明確的途徑。例如，2022年8月，布魯克斯實驗室及其子公司Brooks Steriscience獲得美國食品藥物管理局（USFDA）核准美羅培南注射液（每瓶500毫克、每瓶1克）產品，宣布被收購。本品為學名藥，相當於輝瑞公司的美瑞注射液。

然而，過度使用和濫用抗生素（包括碳青黴烯類）會導致抗菌素抗藥性（AMR）的產生。隨著細菌不斷進化並對這些藥物產生抗藥性，它們治療感染疾病的有效性將會下降，對碳青黴烯類和其他抗生素構成重大挑戰。

碳青黴烯市場報告亮點

  • 按藥物類別分類，美羅培南細分市場由於其對多種細菌（包括多重抗藥性菌株）具有廣譜活性，將在 2022 年佔據市場主導地位。其他細分市場預計將以最快的年複合成長率成長。
  • 從用途來看，尿道感染（UTI）領域預計將在 2022 年佔據最大的市場佔有率，並見證最快的成長速度。尿道感染被認為是全世界最常見的細菌感染疾病。
  • 從配銷通路來看，由於細菌感染疾病患病不斷上升，醫院藥房預計將在 2022 年佔據市場主導地位，並以最快的年複合成長率成長。
  • 2022 年，由於主要市場參與者和強大的醫療基礎設施的存在，北美主導了市場。因此，該地區的碳青黴烯市場預計在預測期內將擴大。
  • 由於印度和中國等開發中國家尿道結石患病、醫療支出增加以及醫療基礎設施改善，亞太地區預計在預測期內將以最快的速度成長。

目錄

第1章 碳青黴烯市場：調查方法與範圍

第2章 碳青黴烯市場：執行摘要

  • 市場概述
  • 產品類型和用途概況
  • 配銷通路簡介
  • 競爭形勢概覽

第3章 碳青黴烯類市場變數、趨勢與範圍

  • 市場區隔和範圍
  • 市場體系預測
    • 母市場預測
    • 相關/附隨市場預測
  • 市場動態
  • 市場促進因素分析
    • 抗生素抗藥性感染疾病的傳播
    • 臨床研究的大量研發投資
  • 市場抑制因素分析
    • 碳青黴烯類生產成本高
    • 副作用和安全問題
  • 波特五力分析
  • PESTLE分析

第4章 碳青黴烯類市場：藥物類別估計與趨勢分析

  • 碳青黴烯類市場：藥物類別變異分析
  • 美羅培南
  • 亞胺培南
  • 厄他培南
  • 其他

第5章 碳青黴烯類市場：用途估算與趨勢分析

  • 碳青黴烯類市場：用途變化分析
  • 尿道感染
  • 血流感染疾病
  • 腹腔內感染疾病
  • 肺炎
  • 其他

第6章 碳青黴烯類市場：配銷通路估算與趨勢分析

  • 碳青黴烯市場：配銷通路波動分析
  • 醫院藥房
  • 零售藥房
  • 其他

第7章 碳青黴烯市場：區域業務分析

  • 區域市場概述
  • 北美洲
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東/非洲

第8章 碳青黴烯市場：競爭形勢

  • 公司分類
  • 策略規劃
  • 2022年主要企業市場佔有率分析
  • 企業熱力圖分析
  • 公司簡介
Product Code: GVR-4-68040-118-4

Carbapenem Market Growth & Trends:

The global carbapenem market size is expected to reach USD 5.24 billion by 2030, according to a new report by Grand View Research, Inc.., exhibiting a CAGR of 4.78% from 2023 to 2030. The rise in the utilization of carbapenem-based antibiotics, elevated prescription rates of antibiotics, and progress in research and development resulting in the upcoming novel medications; are a few of the factors that are anticipated to propel the growth of the market over the forecast period.

According to an American Lung Association article, published in November 2022, Pneumonia is more prevalent than commonly perceived, leading to over a million hospitalizations and causing more than 50,000 deaths annually. In May 2023, Antabio initiated its Phase I trial by administering the initial dose of antibiotic therapy to healthy volunteers for hospital-acquired infections. The therapy, known as MEM-ANT3310, combines meropenem (MEM) with Antabio's novel broad-spectrum serine beta-lactamase inhibitor, ANT3310. This is fueling the growth of the market over the forecast period.

Moreover, during the pandemic, healthcare systems worldwide faced immense challenges in managing severe cases of COVID-19, especially in ICU settings. Many critically ill COVID-19 patients required advanced medical care, including the use of antibiotics to address secondary bacterial infections. Carbapenems, being potent broad-spectrum antibiotics, were one of the treatment options considered for bacterial co-infections in these patients. Thus, there was a significant impact during the period of the COVID-19 pandemic on the market.

The regulatory framework for pharmaceuticals in North America, particularly in the United States, is well-established and provides a clear pathway for drug approvals. For instance, in August 2022, Brooks Laboratories made an announcement stating that its subsidiary, Brooks Steriscience, has obtained approval from the United States Food & Drug Administration (USFDA) for the product, Meropenem Injection, available in 500mg per vial and 1gram per vial. This product serves as the generic equivalent to Pfizer Inc.'s Merrem Injection.

However, the overuse and misuse of antibiotics, including carbapenems, contribute to the development of antimicrobial resistance (AMR). As bacteria continue to evolve and become resistant to these drugs, their effectiveness in treating infections diminishes, posing a significant challenge for carbapenems and other antibiotics.

Carbapenem Market Report Highlights:

  • Based on drug class, the meropenem segment dominated the market in 2022, owing to their broad-spectrum activity against various bacteria, including multidrug-resistant strains. Other segment is anticipated to grow at the fastest CAGR rate
  • Based on application, the urinary tract infections (UTIs) segment held the largest share of the market in 2022 and is anticipated to grow at the fastest growth rate. UTIs are considered to be the most common bacterial infections across the globe
  • Based on the distribution channel, the hospital pharmacies segment dominated the market in 2022 and is anticipated to grow at the fastest CAGR rate owing to the rising prevalence of bacterial infections
  • In 2022, North America dominated the market, owing to the presence of major market players, and robust healthcare infrastructure. These are anticipated to boost the market for carbapenem in the region over the forecast period
  • Asia Pacific is anticipated to grow at the fastest growth rate over the forecast period due to the high prevalence of UTIs, growing healthcare spending, and the development of healthcare infrastructure in developing countries like India and China

Table of Contents

Chapter 1. Carbapenem Market: Methodology and Scope

  • 1.1. Market Segmentation and Scope
    • 1.1.1. Segment Definitions
      • 1.1.1.1. Product Type Segment
      • 1.1.1.2. Drug Class Segment
      • 1.1.1.3. Application Segment
      • 1.1.1.4. Distribution Channel Segment
  • 1.2. Regional Scope
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Objectives
    • 1.4.1. Objective - 1
    • 1.4.2. Objective - 2
    • 1.4.3. Objective - 3
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. GVR's Internal Database
    • 1.6.3. Secondary Sources
    • 1.6.4. Primary Research
  • 1.7. Information or Data Analysis
    • 1.7.1. Data Analysis Models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity Flow Analysis
  • 1.10. List of Secondary Sources
  • 1.11. List of Abbreviations

Chapter 2. Carbapenem Market: Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Product Type and Application Snapshot
  • 2.3. Distribution Channel Snapshot
  • 2.4. Competitive Landscape Snapshot

Chapter 3. Carbapenem Market Variables, Trends, & Scope

  • 3.1. Market Segmentation and Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Dynamics
  • 3.4. Market Drivers Analysis
    • 3.4.1. Increasing prevalence of antibiotic-resistant infections
    • 3.4.2. High R&D investments in clinical research
  • 3.5. Market Restraint Analysis
    • 3.5.1. High cost of production of carbapenem-based antibiotics
    • 3.5.2. Side effects and safety concerns
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. Carbapenem Market: Drug Class Estimates & Trend Analysis

  • 4.1. Carbapenem Market: Drug Class Movement Analysis
  • 4.2. Meropenem
    • 4.2.1. Meropenem Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.3. Imipenem
    • 4.3.1. Imipenem Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Ertapenem
    • 4.4.1. Ertapenem Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Others
    • 4.5.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Carbapenem Market: Application Estimates & Trend Analysis

  • 5.1. Carbapenem Market: Application Movement Analysis
  • 5.2. Urinary Tract Infections
    • 5.2.1. Urinary Tract Infections Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.3. Bloodstream Infections
    • 5.3.1. Bloodstream Infections Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Intra-abdominal Infections
    • 5.4.1. Intra-abdominal Infections Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Pneumonia
    • 5.5.1. Pneumonia Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Others
    • 5.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Carbapenem Market: Distribution Channel Estimates & Trend Analysis

  • 6.1. Carbapenem Market: Distribution Channel Movement Analysis
  • 6.2. Hospital Pharmacies
    • 6.2.1. Hospital Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.3. Retail Pharmacies
    • 6.3.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Others
    • 6.4.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Carbapenem Market: Regional Business Analysis

  • 7.1. Regional Market Snapshot
  • 7.2. North America
    • 7.2.1. North America Carbapenem Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Carbapenem Market, 2018 - 2030 (USD Million)
      • 7.2.2.2. Key Country Dynamics
      • 7.2.2.3. Regulatory Framework
      • 7.2.2.4. Reimbursement Scenario
      • 7.2.2.5. Competitive Scenario
    • 7.2.3. Canada
      • 7.2.3.1. Canada Carbapenem Market, 2018 - 2030 (USD Million)
      • 7.2.3.2. Key Country Dynamics
      • 7.2.3.3. Regulatory Framework
      • 7.2.3.4. Reimbursement Scenario
      • 7.2.3.5. Competitive Scenario
  • 7.3. Europe
    • 7.3.1. Europe Carbapenem Market, 2018 - 2030 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. UK Carbapenem Market, 2018 - 2030 (USD Million)
      • 7.3.2.2. Key Country Dynamics
      • 7.3.2.3. Regulatory Framework
      • 7.3.2.4. Reimbursement Scenario
      • 7.3.2.5. Competitive Scenario
    • 7.3.3. Germany
      • 7.3.3.1. Germany Carbapenem Market, 2018 - 2030 (USD Million)
      • 7.3.3.2. Key Country Dynamics
      • 7.3.3.3. Regulatory Framework
      • 7.3.3.4. Reimbursement Scenario
      • 7.3.3.5. Competitive Scenario
    • 7.3.4. Spain
      • 7.3.4.1. Spain Carbapenem Market, 2018 - 2030 (USD Million)
      • 7.3.4.2. Key Country Dynamics
      • 7.3.4.3. Regulatory Framework
      • 7.3.4.4. Reimbursement Scenario
      • 7.3.4.5. Competitive Scenario
    • 7.3.5. France
      • 7.3.5.1. France Carbapenem Market, 2018 - 2030 (USD Million)
      • 7.3.5.2. Key Country Dynamics
      • 7.3.5.3. Regulatory Framework
      • 7.3.5.4. Reimbursement Scenario
      • 7.3.5.5. Competitive Scenario
    • 7.3.6. Italy
      • 7.3.6.1. Italy Carbapenem Market, 2018 - 2030 (USD Million)
      • 7.3.6.2. Key Country Dynamics
      • 7.3.6.3. Regulatory Framework
      • 7.3.6.4. Reimbursement Scenario
      • 7.3.6.5. Competitive Scenario
    • 7.3.7. Denmark
      • 7.3.7.1. Denmark Carbapenem Market, 2018 - 2030 (USD Million)
      • 7.3.7.2. Key Country Dynamics
      • 7.3.7.3. Regulatory Framework
      • 7.3.7.4. Reimbursement Scenario
      • 7.3.7.5. Competitive Scenario
    • 7.3.8. Sweden
      • 7.3.8.1. Sweden Carbapenem Market, 2018 - 2030 (USD Million)
      • 7.3.8.2. Key Country Dynamics
      • 7.3.8.3. Regulatory Framework
      • 7.3.8.4. Reimbursement Scenario
      • 7.3.8.5. Competitive Scenario
    • 7.3.9. Norway
      • 7.3.9.1. Norway Carbapenem Market, 2018 - 2030 (USD Million)
      • 7.3.9.2. Key Country Dynamics
      • 7.3.9.3. Regulatory Framework
      • 7.3.9.4. Reimbursement Scenario
      • 7.3.9.5. Competitive Scenario
  • 7.4. Asia Pacific
    • 7.4.1. Asia-Pacific Carbapenem Market, 2018 - 2030 (USD Million)
    • 7.4.2. Japan
      • 7.4.2.1. Japan Carbapenem Market, 2018 - 2030 (USD Million)
      • 7.4.2.2. Key Country Dynamics
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. Reimbursement Scenario
      • 7.4.2.5. Competitive Scenario
    • 7.4.3. China
      • 7.4.3.1. China Carbapenem Market, 2018 - 2030 (USD Million)
      • 7.4.3.2. Key Country Dynamics
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Reimbursement Scenario
      • 7.4.3.5. Competitive Scenario
    • 7.4.4. India
      • 7.4.4.1. India Carbapenem Market, 2018 - 2030 (USD Million)
      • 7.4.4.2. Key Country Dynamics
      • 7.4.4.3. Regulatory Framework
      • 7.4.4.4. Reimbursement Scenario
      • 7.4.4.5. Competitive Scenario
    • 7.4.5. South Korea
      • 7.4.5.1. South Korea Carbapenem Market, 2018 - 2030 (USD Million)
      • 7.4.5.2. Key Country Dynamics
      • 7.4.5.3. Regulatory Framework
      • 7.4.5.4. Reimbursement Scenario
      • 7.4.5.5. Competitive Scenario
    • 7.4.6. Thailand
      • 7.4.6.1. Thailand Carbapenem Market, 2018 - 2030 (USD Million)
      • 7.4.6.2. Key Country Dynamics
      • 7.4.6.3. Regulatory Framework
      • 7.4.6.4. Reimbursement Scenario
      • 7.4.6.5. Competitive Scenario
    • 7.4.7. Australia
      • 7.4.7.1. Australia Carbapenem Market, 2018 - 2030 (USD Million)
      • 7.4.7.2. Key Country Dynamics
      • 7.4.7.3. Regulatory Framework
      • 7.4.7.4. Reimbursement Scenario
      • 7.4.7.5. Competitive Scenario
  • 7.5. Latin America
    • 7.5.1. Latin America Carbapenem Market, 2018 - 2030 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Carbapenem Market, 2018 - 2030 (USD Million)
      • 7.5.2.2. Key Country Dynamics
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Reimbursement Scenario
      • 7.5.2.5. Competitive Scenario
    • 7.5.3. Mexico
      • 7.5.3.1. Mexico Carbapenem Market, 2018 - 2030 (USD Million)
      • 7.5.3.2. Key Country Dynamics
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. Reimbursement Scenario
      • 7.5.3.5. Competitive Scenario
    • 7.5.4. Argentina
      • 7.5.4.1. Argentina Carbapenem Market, 2018 - 2030 (USD Million)
      • 7.5.4.2. Key Country Dynamics
      • 7.5.4.3. Regulatory Framework
      • 7.5.4.4. Reimbursement Scenario
      • 7.5.4.5. Competitive Scenario
  • 7.6. MEA
    • 7.6.1. MEA Carbapenem Market, 2018 - 2030 (USD Million)
    • 7.6.2. South Africa
      • 7.6.2.1. South Africa Carbapenem Market, 2018 - 2030 (USD Million)
      • 7.6.2.2. Key Country Dynamics
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. Reimbursement Scenario
      • 7.6.2.5. Competitive Scenario
    • 7.6.3. Saudi Arabia
      • 7.6.3.1. Saudi Arabia Carbapenem Market, 2018 - 2030 (USD Million)
      • 7.6.3.2. Key Country Dynamics
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. Reimbursement Scenario
      • 7.6.3.5. Competitive Scenario
    • 7.6.4. UAE
      • 7.6.4.1. UAE Carbapenem Market, 2018 - 2030 (USD Million)
      • 7.6.4.2. Key Country Dynamics
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. Reimbursement Scenario
      • 7.6.4.5. Competitive Scenario
    • 7.6.5. Kuwait
      • 7.6.5.1. Kuwait Carbapenem Market, 2018 - 2030 (USD Million)
      • 7.6.5.2. Key Country Dynamics
      • 7.6.5.3. Regulatory Framework
      • 7.6.5.4. Reimbursement Scenario
      • 7.6.5.5. Competitive Scenario

Chapter 8. Carbapenem Market: Competitive Landscape

  • 8.1. Company Categorization
  • 8.2. Strategy Mapping
    • 8.2.1. New Product Type Launch
    • 8.2.2. Partnerships
    • 8.2.3. Acquisition
    • 8.2.4. Collaborotion
    • 8.2.5. Funding
  • 8.3. Key Company Market Share Analysis, 2022
  • 8.4. Company Heat Map Analysis
  • 8.5. Company Profiles
    • 8.5.1. The Menarini Group
      • 8.5.1.1. Company Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. Pfizer Inc.
      • 8.5.2.1. Company Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. Sun Pharmaceutical Industries Ltd
      • 8.5.3.1. Company Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. Lupin
      • 8.5.4.1. Company Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Kopran Limited
      • 8.5.5.1. Company Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. Aurobindo Pharma
      • 8.5.6.1. Company Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Product Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Daewoong Pharmaceuticals Co., Ltd.
      • 8.5.7.1. Company Overview
      • 8.5.7.2. Product Benchmarking
      • 8.5.7.3. Strategic Initiatives
    • 8.5.8. Shenzhen Haibin Pharmaceutical Co. Ltd.
      • 8.5.8.1. Company Overview
      • 8.5.8.2. Product Benchmarking
      • 8.5.8.3. Strategic Initiatives
    • 8.5.9. Merck & Co., Inc.
      • 8.5.9.1. Company Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Product Benchmarking
      • 8.5.9.4. Strategic Initiatives
    • 8.5.10. Venus Remedies Ltd
      • 8.5.10.1. Company Overview
      • 8.5.10.2. Financial Performance
      • 8.5.10.3. Product Benchmarking
      • 8.5.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 1 List of abbreviation
  • Table 2 North America carbapenem market, by country, 2018 - 2030 (USD Million)
  • Table 3 North America carbapenem market, by drug class, 2018 - 2030 (USD Million)
  • Table 4 North America carbapenem market, by application, 2018 - 2030 (USD Million)
  • Table 5 North America carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 6 U.S. carbapenem market, by drug class, 2018 - 2030 (USD Million)
  • Table 7 U.S carbapenem market, by application, 2018 - 2030 (USD Million)
  • Table 8 U.S carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 9 Canada carbapenem market, by drug class, 2018 - 2030 (USD Million)
  • Table 10 Canada carbapenem market, by application, 2018 - 2030 (USD Million)
  • Table 11 Canada carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 12 Europe carbapenem market, by country, 2018 - 2030 (USD Million)
  • Table 13 Europe carbapenem market, by drug class, 2018 - 2030 (USD Million)
  • Table 14 Europe carbapenem market, by application, 2018 - 2030 (USD Million)
  • Table 15 Europe carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 16 UK carbapenem market, by drug class, 2018 - 2030 (USD Million)
  • Table 17 UK carbapenem market, by application, 2018 - 2030 (USD Million)
  • Table 18 UK carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 19 Germany carbapenem market, by drug class, 2018 - 2030 (USD Million)
  • Table 20 Germany carbapenem market, by application, 2018 - 2030 (USD Million)
  • Table 21 Germany carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 22 France carbapenem market, by drug class, 2018 - 2030 (USD Million)
  • Table 23 France carbapenem market, by application, 2018 - 2030 (USD Million)
  • Table 24 France carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 25 Italy carbapenem market, by drug class, 2018 - 2030 (USD Million)
  • Table 26 Italy carbapenem market, by application, 2018 - 2030 (USD Million)
  • Table 27 Italy carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 28 Spain carbapenem market, by drug class, 2018 - 2030 (USD Million)
  • Table 29 Spain carbapenem market, by application, 2018 - 2030 (USD Million)
  • Table 30 Spain carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 31 Denmark carbapenem market, by drug class, 2018 - 2030 (USD Million)
  • Table 32 Denmark carbapenem market, by application, 2018 - 2030 (USD Million)
  • Table 33 Denmark carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 34 Sweden carbapenem market, by drug class, 2018 - 2030 (USD Million)
  • Table 35 Sweden carbapenem market, by application, 2018 - 2030 (USD Million)
  • Table 36 Sweden carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 37 Norway carbapenem market, by drug class, 2018 - 2030 (USD Million)
  • Table 38 Norway carbapenem market, by application, 2018 - 2030 (USD Million)
  • Table 39 Norway carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 40 Asia Pacific carbapenem market, by country, 2018 - 2030 (USD Million)
  • Table 41 Asia Pacific carbapenem market, by drug class, 2018 - 2030 (USD Million)
  • Table 42 Asia Pacific carbapenem market, by application, 2018 - 2030 (USD Million)
  • Table 43 Asia Pacific carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 44 China carbapenem market, by drug class, 2018 - 2030 (USD Million)
  • Table 45 China carbapenem market, by application, 2018 - 2030 (USD Million)
  • Table 46 China carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 47 Japan carbapenem market, by drug class, 2018 - 2030 (USD Million)
  • Table 48 Japan carbapenem market, by application, 2018 - 2030 (USD Million)
  • Table 49 Japan carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 50 India carbapenem market, by drug class, 2018 - 2030 (USD Million)
  • Table 51 India carbapenem market, by application, 2018 - 2030 (USD Million)
  • Table 52 India carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 53 South Korea carbapenem market, by drug class, 2018 - 2030 (USD Million)
  • Table 54 South Korea carbapenem market, by application, 2018 - 2030 (USD Million)
  • Table 55 South Korea carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 56 Australia carbapenem market, by drug class, 2018 - 2030 (USD Million)
  • Table 57 Australia carbapenem market, by application, 2018 - 2030 (USD Million)
  • Table 58 Australia carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 59 Thailand carbapenem market, by drug class, 2018 - 2030 (USD Million)
  • Table 60 Thailand carbapenem market, by application, 2018 - 2030 (USD Million)
  • Table 61 Thailand carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 62 Latin America carbapenem market, by country, 2018 - 2030 (USD Million)
  • Table 63 Latin America carbapenem market, by drug class, 2018 - 2030 (USD Million)
  • Table 64 Latin America carbapenem market, by application, 2018 - 2030 (USD Million)
  • Table 65 Latin America carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 66 Brazil carbapenem market, by drug class, 2018 - 2030 (USD Million)
  • Table 67 Brazil carbapenem market, by application, 2018 - 2030 (USD Million)
  • Table 68 Brazil carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 69 Mexico carbapenem market, by drug class, 2018 - 2030 (USD Million)
  • Table 70 Mexico carbapenem market, by application, 2018 - 2030 (USD Million)
  • Table 71 Mexico carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 72 Argentina carbapenem market, by drug class, 2018 - 2030 (USD Million)
  • Table 73 Argentina carbapenem market, by application, 2018 - 2030 (USD Million)
  • Table 74 Argentina carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 75 Middle East & Africa carbapenem market, by country, 2018 - 2030 (USD Million)
  • Table 76 Middle East & Africa carbapenem market, by drug class, 2018 - 2030 (USD Million)
  • Table 77 Middle East & Africa carbapenem market, by application, 2018 - 2030 (USD Million)
  • Table 78 Middle East & Africa carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 79 South Africa carbapenem market, by drug class, 2018 - 2030 (USD Million)
  • Table 80 South Africa carbapenem market, by application, 2018 - 2030 (USD Million)
  • Table 81 South Africa carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 82 Saudi Arabia carbapenem market, by drug class, 2018 - 2030 (USD Million)
  • Table 83 Saudi Arabia carbapenem market, by application, 2018 - 2030 (USD Million)
  • Table 84 Saudi Arabia carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 85 UAE carbapenem market, by drug class, 2018 - 2030 (USD Million)
  • Table 86 UAE carbapenem market, by application, 2018 - 2030 (USD Million)
  • Table 87 UAE carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 88 Kuwait carbapenem market, by drug class, 2018 - 2030 (USD Million)
  • Table 89 Kuwait carbapenem market, by application, 2018 - 2030 (USD Million)
  • Table 90 Kuwait carbapenem market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Market summary
  • Fig. 4 Market segmentation & scope
  • Fig. 5 Market size and growth prospects
  • Fig. 6 Global carbapenem market - Key market driver analysis
  • Fig. 7 Global carbapenem market - Key market restraint analysis
  • Fig. 8 Penetration & growth prospect mapping
  • Fig. 9 Global carbapenem market - Porter's analysis
  • Fig. 10 Global carbapenem market - PESTEL analysis
  • Fig. 11 Global carbapenem market drug class outlook key takeaways
  • Fig. 12 Global carbapenem market: Drug class movement analysis
  • Fig. 13 Meropenem market estimates, 2018 - 2030 (USD Million)
  • Fig. 14 Imipenem market estimates, 2018 - 2030 (USD Million)
  • Fig. 15 Ertapenem market estimates, 2018 - 2030 (USD Million)
  • Fig. 16 Others market estimates, 2018 - 2030 (USD Million)
  • Fig. 17 Global carbapenem market application outlook key takeaways
  • Fig. 18 Global carbapenem market: application movement analysis
  • Fig. 19 Urinary tract infections market estimates, 2018 - 2030 (USD Million)
  • Fig. 20 Bloodstream infections market estimates, 2018 - 2030 (USD Million)
  • Fig. 21 Pneumonia market estimates, 2018 - 2030 (USD Million)
  • Fig. 22 Intra - abdominal infections market estimates, 2018 - 2030 (USD Million)
  • Fig. 23 Others market estimates, 2018 - 2030 (USD Million)
  • Fig. 24 Global carbapenem market distribution channel outlook key takeaways
  • Fig. 25 Global carbapenem market: Test type movement analysis
  • Fig. 26 Hospital pharmacies market estimates, 2018 - 2030 (USD Million)
  • Fig. 27 Retail pharmacies market estimates, 2018 - 2030 (USD Million)
  • Fig. 28 Others market estimates, 2018 - 2030 (USD Million)
  • Fig. 29 Regional marketplace: Key takeaways
  • Fig. 30 Global carbapenem market: Regional movement analysis
  • Fig. 31 North America carbapenem market, 2018 - 2030 (USD Million)
  • Fig. 32 U.S. carbapenem market, 2018 - 2030 (USD Million)
  • Fig. 33 Canada carbapenem market, 2018 - 2030 (USD Million)
  • Fig. 34 Europe carbapenem market, 2018 - 2030 (USD Million)
  • Fig. 35 UK carbapenem market, 2018 - 2030 (USD Million)
  • Fig. 36 Germany carbapenem market, 2018 - 2030 (USD Million)
  • Fig. 37 France carbapenem market, 2018 - 2030 (USD Million)
  • Fig. 38 Spain carbapenem market, 2018 - 2030 (USD Million)
  • Fig. 39 Italy carbapenem market, 2018 - 2030 (USD Million)
  • Fig. 40 Denmark carbapenem market, 2018 - 2030 (USD Million)
  • Fig. 41 Sweden carbapenem market, 2018 - 2030 (USD Million)
  • Fig. 42 Norway carbapenem market, 2018 - 2030 (USD Million)
  • Fig. 43 Asia Pacific carbapenem market, 2018 - 2030 (USD Million)
  • Fig. 44 Japan carbapenem market, 2018 - 2030 (USD Million)
  • Fig. 45 China carbapenem market, 2018 - 2030 (USD Million)
  • Fig. 46 India carbapenem market, 2018 - 2030 (USD Million)
  • Fig. 47 South Korea carbapenem market, 2018 - 2030 (USD Million)
  • Fig. 48 Australia carbapenem market, 2018 - 2030 (USD Million)
  • Fig. 49 Thailand carbapenem market, 2018 - 2030 (USD Million)
  • Fig. 50 Latin America carbapenem market, 2018 - 2030 (USD Million)
  • Fig. 51 Brazil carbapenem market, 2018 - 2030 (USD Million)
  • Fig. 52 Mexico carbapenem market, 2018 - 2030 (USD Million)
  • Fig. 53 Argentina carbapenem market, 2018 - 2030 (USD Million)
  • Fig. 54 MEA carbapenem market, 2018 - 2030 (USD Million)
  • Fig. 55 South Africa carbapenem market, 2018 - 2030 (USD Million)
  • Fig. 56 Saudi Arabia carbapenem market, 2018 - 2030 (USD Million)
  • Fig. 57 UAE carbapenem market, 2018 - 2030 (USD Million)
  • Fig. 58 Kuwait carbapenem market, 2018 - 2030 (USD Million)
  • Fig. 59 Strategy framework